Sponsor Directory

AstraZeneca clinical trials

Sponsor pages show live ClinicalTrials.gov search results and objective aggregate stats only. They do not describe sponsor quality, reputation, or expected outcomes.

ClinicalTrials.gov public records Last synced Nov 7, 2026, 4:32 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials

1904

Shown on this page

Current sort

Live official records

Open in full search

Conditions: Constipation, Critical Illness
Interventions: Polyethylene glycol, naloxegol; Drug
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Heart Failure With Reduced Ejection Fraction (HFrEF)
Interventions: Dapagliflozin, Placebo; Drug · Other
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 150 Years
Enrollment: 313 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 23
States / cities: Alexander City, Alabama • Fairhope, Alabama • Fort Payne, Alabama + 19 more

Conditions: Endometrial Cancer, Ovarian Cancer, Cervical Cancer, Fallopian Tube Cancer, Peritoneal Cancer
Interventions: temsirolimus, cediranib; Drug
Lead sponsor: Susana M. Campos, MD; Other
Eligibility: 18 Years and older · Female only
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2021
U.S. locations: 3
States / cities: Boston, Massachusetts

Conditions: Papillary Renal Cell Cancer
Interventions: AZD6094; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 99 Years
Enrollment: 111 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2020
U.S. locations: 13
States / cities: Birmingham, Alabama • Duarte, California • Palo Alto, California + 10 more

Conditions: Asthma
Interventions: Benralizumab; Biological
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 130 Years
Enrollment: 447 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2020
U.S. locations: 52
States / cities: Scottsboro, Alabama • Glendale, Arizona • Phoenix, Arizona + 42 more

Conditions: Primary Peritoneal Carcinoma
Interventions: Tremelimumab, Olaparib; Drug
Lead sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Other
Eligibility: 18 Years and older
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2020
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Sickle Cell Disease
Interventions: Ticagrelor, Placebo; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 2 Years to 17 Years
Enrollment: 193 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 7
States / cities: Fort Lauderdale, Florida • Miami, Florida • Chicago, Illinois + 4 more

Conditions: Heart Failure With Preserved Ejection Fraction (HFpEF)
Interventions: AZD4831, Placebo; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 50 Years · Male only
Enrollment: 32 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: Glendale, California

Conditions: Ovarian Cancer
Interventions: Olaparib, Ceralasertib, Placebo to match olaparib; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 130 Years · Female only
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 22
States / cities: Anchorage, Alaska • La Jolla, California • Long Beach, California + 18 more

Conditions: Asthma
Interventions: Benralizumab; Drug
Lead sponsor: National Jewish Health; Other
Eligibility: 18 Years to 100 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2021
U.S. locations: 1
States / cities: Denver, Colorado

Conditions: Diabetes Mellitus Type 2
Interventions: Not listed
Lead sponsor: AstraZeneca; Industry
Eligibility: Not listed
Enrollment: 99,999 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 1
States / cities: Wilmington, Delaware

Conditions: Type 2 Diabetes
Interventions: Dapagliflozin, Metformin, Placebo; Drug
Lead sponsor: University of Miami; Other
Eligibility: 18 Years to 64 Years
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2020
U.S. locations: 1
States / cities: Miami, Florida

About this AstraZeneca sponsor directory page

What this page lists: U.S. ClinicalTrials.gov public records where AstraZeneca is the lead sponsor, including recruiting, not yet recruiting, and active not recruiting trials across phase 1, phase 2, and phase 3.
How to narrow results: Use the filters above to scope by condition, intervention, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, age, or NCT ID within AstraZeneca trials.
Where the data comes from: Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
What this page does not do: No medical advice, eligibility judgments, sponsor quality scoring, ranking of trials, or AI-generated medical summaries.

AstraZeneca clinical trials

Filter and sort this sponsor

Live official records

The Effect of Naloxegol on Refractory Constipation in the Intensive Care Unit

DETERMINE-reduced - Dapagliflozin Effect on Exercise Capacity Using a 6-minute Walk Test in Patients With Heart Failure With Reduced Ejection Fraction

AZD2171 and Temsirolimus in Patients With Advanced Gynecological Malignancies

A Phase II Trial to Evaluate the Efficacy of AZD6094 (HMPL-504) in Patients With Papillary Renal Cell Carcinoma (PRCC)

A Safety Extension Study With Benralizumab for Asthmatic Adults on Inhaled Corticosteroid Plus Long-acting β2 Agonist

Study of Tremelimumab Alone or Combined With Olaparib for Patients With Persistent EOC (Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Carcinoma)

Effect of Ticagrelor vs. Placebo in the Reduction of Vaso-occlusive Crises in Pediatric Patients With Sickle Cell Disease

A Study to Assess the Effect AZD4831 in Japanese and Chinese Healthy Volunteers

A Study to Evaluate the Effectiveness and Tolerability of a Second Maintenance Treatment in Participants With Ovarian Cancer, Who Have Previously Received Polyadenosine 5'Diphosphoribose [Poly (ADP Ribose)] Polymerase Inhibitor (PARPi) Treatment.

Benralizumab in the Treatment of Eosinophilic Granulomatosis With Polyangiitis (EGPA) Study

Comparative Effectiveness of Cardiovascular Outcomes in New Users of SGLT-2 Inhibitors

Dapagliflozin Effects on Epicardial Fat

About this AstraZeneca sponsor directory page